Printed and Online Press

Beta Bioniocs - Nature Medicine.jpg

Mission Control: Drug Developers Test the 'benefit Corporation' Business Model

Beta Bioniocs - BUToday.png

On the heels of winning $12 million in supplemental funding from the National Institutes of Health (NIH) to conduct a major, multicenter, national clinical trial of his iLet™ bionic pancreas ...

f46be7_a0a5acac91834ee1a86676aa190685bb.

Beta Bionics shared exclusive breaking news with diaTribe today that it has received an impressive $5 million investment from insulin maker Novo Nordisk in its newest strategic partnership. 

​That passionate investor base was evident in another of Wefunder’s $1 million campaigns: an experimental medical device for Type 1 diabetes produced by Beta Bionics, a startup headed by Boston University professor Ed Damiano.

Beta Bionics NIH (1).png

A bionic pancreas system improved blood glucose control in adults with type 1 diabetes better than conventional insulin pump therapy

Beta Bionics - WRAL.jpg

Type 1 diabetes does not have a cure. Living with the condition is also time consuming, but science is working to make that treatment a little bit easier.

Beta Bionics SA (2).jpg

Devices that autonomously regulate blood sugar levels are in the final stages before widespread availability

Congressional_Record_2016 (1).png

Ed Damiano featured in the 2016 Congressional Record celebrating the Endocrine Society centennial anniversary

Beta Bioniocs - BUToday.png

Ed Damiano has devoted more than a decade to develop a bionic pancreas

Beta Bioniocs - Healio.png

Patients with type 1 diabetes receiving glucagon from an automatic bionic pancreas experienced fewer symptomatic hypoglycemia episodes compared with those receiving placebo, according to a presenter here.

Beta Bioniocs -PR Newswire.png

"Our study found that using automatic glucagon delivery reduced hypoglycemia by 75 percent during the day and 91 percent at night," said lead investigator Courtney Balliro, RN, BS, CDE, Clinical Research Nurse at the MGH Diabetes Research Center, Boston, MA.

Beta Bioniocs - ABC.png

Starting today, companies using crowdfunding websites to raise money can offer stock options to donors.

Beta Bioniocs - Boston Globe.png

Under federal rules taking, private companies can sell shares online to virtually anyone.

Beta Bioniocs - Dmine.png

Meet Beta Bionics: New Business Structure for iLet Bionic Pancreas

Say hello to Beta Bionics, the new parent company that plans to commercialize the exciting iLet Bionic Pancreas system that administers both insulin and glucagon and was famously developed by researcher and diabetes dad Dr. Ed Damiano at Boston University.

Beta Bioniocs - BUToday.png

Hope for the Battle against Type 1 Diabetes

Ed Damiano, a Boston University professor of biomedical engineering and the father of a 16-year-old boy with type 1 diabetes, has been racing for nearly 13 years to develop an artificial, or bionic, pancreas that could transform the lives of millions of people who have the same disease as his son, freeing them from the round-the-clock burden of managing a potentially life-threatening disorder themselves.

Beta Bioniocs - Time.png

The Bionic Pancreas Is Getting Closer to Reality

CAUTION: The iLet® bionic pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale.

© 2020 Beta Bionics, Inc. Beta Bionics® and iLet® are registered trademarks of Beta Bionics, Inc. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.